These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27317516)

  • 21. Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.
    Zagouri F; Roussou M; Kastritis E; Koureas A; Tsokou E; Migkou M; Gavriatopoulou M; Nikitas N; Gkotzamanidou M; Terpos E; Dimopoulos MA
    Am J Hematol; 2011 Oct; 86(10):882-4. PubMed ID: 21818766
    [No Abstract]   [Full Text] [Related]  

  • 22. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide in myelodysplastic syndromes.
    List AF
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):271-2, 311. PubMed ID: 18496493
    [No Abstract]   [Full Text] [Related]  

  • 25. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pomalidomide: when expectations are understated.
    Di Raimondo F; Conticello C
    Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
    [No Abstract]   [Full Text] [Related]  

  • 28. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
    Musto P; Pietrantuono G; Guariglia R; Villani O; Martorelli MC; D'Auria F; Zonno A; Lerose R
    Leuk Res; 2008 Oct; 32(10):1637-8. PubMed ID: 18433866
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis.
    Giv MJ; Yoosuff A; Bazargan A
    Chest; 2015 Aug; 148(2):e35-e37. PubMed ID: 26238834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.
    Ramsay AG; Gribben JG
    Haematologica; 2009 Sep; 94(9):1198-202. PubMed ID: 19734414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide and thalidomide in the treatment of chronic pain.
    Asher C; Furnish T
    Expert Opin Drug Saf; 2013 May; 12(3):367-74. PubMed ID: 23442012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
    Leitch HA; Buckstein R; Shamy A; Storring JM
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaemia with inflammation responding to lenalidomide.
    Haroun F; Mener A; Elkon J; Tabbara I
    BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27737867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the use of lenalidomide for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2015; 16(12):1865-77. PubMed ID: 26165832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
    Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
    Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
    [No Abstract]   [Full Text] [Related]  

  • 37. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
    Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
    Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide for mantle cell lymphoma.
    Skarbnik AP; Goy AH
    Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide: an immunomodulatory drug.
    Crane E; List A
    Future Oncol; 2005 Oct; 1(5):575-83. PubMed ID: 16556034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.